在中,药物针对PSMB8作为急性髓性白血病治疗的潜在目标进行了重新定位
Ezgi Yağmur Tükel1, Onur Ateş1, Yağmur Kiraz2
1Department of Genetics and Bioengineering, Faculty of Engineering, İzmir University of Economics, Sakarya st. No:156, 35330, Balçova, İzmir, Turkey.
Molecular biotechnology
|July 2, 2024
概括
这项研究选了抑制PSMB8的药物,PSMB8是一种与癌症存活相关的基因. 菲杜克索辛作为一种潜在的急性髓性白血病 (AML) 治疗方法,通过解决与高PSMB8激活相关的低生存率,显示出了希望.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 计算化学计算化学
背景情况:
- PSMB8与癌症存活有关,但其在急性髓性白血病 (AML) 中的作用尚不清楚.
- 准PSMB8为AML提供了一个潜在的治疗策略.
研究的目的:
- 从大型分子图书馆中识别潜在的PSMB8抑制剂.
- 评估候选分子在AML中的治疗潜力.
主要方法:
- 从ZINC15数据库中使用分子对接 (AutoDock) 来虚拟选化合物.
- 对选定的候选人进行ADMET分析 (AdmetSar,SwissADME) 和分子动力学模拟 (GROMACS).
- 对结合亲和力,药理动力学特性和毒性的评估.
主要成果:
- 根据生物可用性和毒性概况,Adozelesin,Fiduxosin和Rimegepant被确定为有前途的候选药物.
- 费杜克索辛证明了与PSMB8.8形成键的显著潜力.
- 菲杜克索辛可以抵消与高PSMB8活性相关的AML的低生存率.
结论:
- 菲杜克索辛通过向PSMB8.8而成为AML的潜在治疗剂.
- 重用现有药物,如菲杜克索辛,为AML治疗提供了更快的途径,绕过了新药开发.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


